Single-institution experience of SBRT for lung metastases in sarcoma patients

Viacheslav Soyfer*, Benjamin W. Corn, Natan Shtraus, Nir Honig, Yaron Meir, Jehuda Kollender, Ofer Merimsky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objectives: Lung metastasectomy is regarded as the standard procedure for improving the prognosis of patients with metastatic sarcoma. Few reports are available in the literature describing the value of stereotactic body radiation therapy (SBRT) of lung metastases from primary sarcoma as an alternative to surgical treatment. We therefore sought to expand the evidence base for this modality. Materials and Methods: Twenty-two patients with metastatic sarcoma to lung were treated by SBRT. The retrospective analysis of overall survival, toxicity, and local control of 53 treated lesions is presented in the study. Lung lesions were grouped into 2 categories for follow-up: <10mm or Z10mm diameter. Results: Of 34 lesions <10 mm, 24 achieved complete response, 3 partial response, and 7 stable disease. The results of 18 lesions measuring >10mm were as follows: 5 complete response, 5 progressive disease, and 8 stable disease. No progressive disease of all SBRT treated lesions was found at a median follow-up of 95 months (SD 32). Five-year overall survival of the entire group was 62% from the time of diagnosis and 50% from start of treatment. The treatment was well tolerated with minimal, mainly skin toxicity.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number1
StatePublished - 2017


  • Lung
  • Metastases
  • SBRT
  • Sarcoma


Dive into the research topics of 'Single-institution experience of SBRT for lung metastases in sarcoma patients'. Together they form a unique fingerprint.

Cite this